Entries by

15 Years ARTES Biotechnology

Toady, ARTES has 15 year anniver­sary. In 2002 at May 10th Michael Pio­ntek found­ed ARTES as R&D com­pa­ny, spe­cial­ized in devel­op­ing yeast cell lines for recom­bi­nant pro­tein pro­duc­tion. In 15 years ARTES has posi­tioned itself as val­ued part­ner for the phar­ma­ceu­ti­cal and life sci­ence indus­try and it is now spe­cial­ized in devel­op­ing whole biotech­nol­o­gy pro­duc­tion processes.

ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum. This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event. ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar about the […]

ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran  ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran. The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) based […]

Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016  Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­­cle (VLP) based tetrava­lent dengue vac­cine, containing […]

ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

ARTES Biotech­nol­o­gy and Bur­net Insti­tute announce they have joined forces to devel­op a nov­el, effec­tive vac­cine to pre­vent trans­mis­sion of hepati­tis C virus (HCV). An HCV vac­cine is urgent­ly need­ed to pre­vent re-infec­­tion in peo­ple treat­ed through antivi­ral ther­a­pies and reverse the high glob­al mor­tal­i­ty rates from infec­­tion-relat­ed liv­er cir­rho­sis or liv­er can­cer, esti­mat­ed by […]

ARTES and Biosphere announce collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for recom­bi­nant pro­tein pro­duc­tion and tech­nol­o­gy provider for high-qual­i­­ty biotech­no­log­i­cal process­es, join forces with the well-estab­lished con­tract man­u­fac­tur­ing com­pa­ny Bios­phere. Aim of this pre­ferred coop­er­a­tion is to offer a full range of ser­vices, start­ing from cell line gen­er­a­tion up to indus­tri­al scale man­u­fac­tur­ing in one […]

ARTES offers manufacturing of preclinical samples up to multi-gram scale

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for the phar­ma­ceu­ti­cal indus­try recent­ly expand­ed its ser­vice port­fo­lio and sup­plied sam­ples for pre­clin­i­cal test­ing to a first client. “With the new equipped pilot plant for pro­duc­tion of nonGMP mate­r­i­al, we are now in the posi­tion to pro­vide our clients with high qual­i­ty pre­clin­i­cal test […]

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion, process and vac­cine devel­op­ment from micro­bial expres­sion sys­tems announces a col­lab­o­ra­tion with the glob­al phar­ma­ceu­ti­cal com­pa­ny Boehringer Ingel­heim Ani­mal Health. ARTES’ expres­sion sys­tem Hansenu­la poly­mor­pha is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and rec­om­mend­ed by the World Health Orga­ni­za­tion (WHO) for these pur­pos­es. In com­bi­na­tion with ARTES’ […]